Pheast Therapeutics Accelerates Development of Immuno-oncology Candidate PHST001 with Clinical Data Release and Entry into Phase 1b Trial
Emergence of the CD24-Targeting Immuno-oncology Market and the Launch of Feast
Pheast Therapeutics, a biotech company specializing in immuno-oncology, was founded in 2021 based on the pioneering research of Dr. Irv Weissman from Stanford University. In 2019, Dr. Weissman published a Nature paper revealing that the CD24 protein is a key 'Don't eat me' signal used by cancer cells to evade phagocytosis by macrophages. This academic breakthrough attracted significant global attention, and in April 2022, Pheast successfully raised USD 76 million in Series A funding led by Catalio Capital and ARCH Venture Partners. Leveraging this capital, Pheast has been developing PHST001, an IgG4-based macrophage checkpoint inhibitor targeting CD24, and has emerged as a key player in the global immuno-oncology market.
Antengene's Clinical Lead and Pheast's Transparency Strategy
Despite leading in foundational research, Pheast found itself following in clinical development, as Antengene (6996.HK), a Chinese company, initiated its Phase 1 trial (PERFORM, NCT06028373) for its CD24-targeting candidate ATG-031 in the U.S. in 2023, entering the clinical stage ahead of Pheast. While this has sparked industry discussions on the importance of pipeline confidentiality, Pheast's CEO, Dr. Roy Maute, has firmly committed to maintaining research transparency, confident in the company's differentiated target approach. Rather than avoiding competition, Pheast has chosen a direct strategy to build early trust with global investors and research partners by publicly demonstrating its unique genomic screening platform and overwhelming data.
Clinical Efficacy of PHST001 Proven at AACR 2026
The success of Pheast's transparency strategy began to materialize in April 2026, when interim Phase 1a data for PHST001 was presented at the AACR 2026 Annual Meeting. The data showed that PHST001 demonstrated excellent tolerability in patients with advanced solid tumors, with most treatment-related adverse events (AEs) classified as Grade 1 or 2. Some patients experienced transient neutrophil decreases, but these were manageable without clinical complications. Early signals of clinical efficacy, including disease control and tumor size reduction, were also observed. These results are a key indicator that Pheast's PHST001 may overcome the severe hematological toxicities previously seen with CD47-targeting therapies, drawing strong interest from clinicians and investors alike.
Strategic Implications of Phase 1b Initiation and Next-Generation Pipeline Development
Building on the encouraging Phase 1a results, Pheast has now initiated a Phase 1b trial to evaluate the combination efficacy of PHST001 with chemotherapy, with data expected to be released next year. In May 2026, the company also disclosed preclinical data for PHST677, a dual-specific antibody-drug conjugate (ADC) candidate targeting both Nectin-4 and CDH1, further accelerating pipeline diversification. In a landscape marked by uncertainties following setbacks such as Gilead's Magrolimab failure in macrophage-targeting therapies, Pheast's data-driven and transparent approach has become a powerful tool for maintaining market trust. Ultimately, these efforts are raising the technical barriers to entry in next-generation immuno-oncology and positioning the company for potential large-scale license-out agreements with global big pharma players.
In the wake of repeated clinical failures of CD47-targeting immuno-oncology drugs, Pheast's CD24-targeting candidate PHST001 is gaining attention as a strong alternative for next-generation checkpoint inhibitors. While Antengene's (6996.HK) competing drug ATG-031 is pursuing a U.S. Phase 1 trial, Pheast has secured high safety data (Grade 1/2) and entered Phase 1b. The Phase 1b combination trial of PHST001, supported by USD 76 million in Series A funding, and the progress of the dual-specific ADC PHST677 are key catalysts for near-term valuation growth. In the long term, PHST001 is positioned as a core pipeline for treating the 40-60% of patients who do not respond to existing PD-1/PD-L1 therapies, in a global immuno-oncology market projected to exceed USD 30 billion by the mid-2030s. Pheast's transparent data-sharing strategy will serve as a critical asset in maintaining scientific objectivity amid intensifying technological competition, maximizing partnership and licensing negotiation power with big pharma.